NanoString, MD Anderson to Collaborate on Combination Gene, Protein Assays | GenomeWeb

NEW YORK (GenomeWeb) – NanoString Technologies today announced that it has formed a multi-year collaboration with the University of Texas MD Anderson Cancer Center to develop and test cancer biomarker assays that simultaneously profile gene and protein expression using the company's nCounter Analysis System.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.